ISSN: 1859 - 2872
Evaluating treatment outcomes of dexlansoprazole 60mg on severe gastroesophageal reflux disease patients
Main Article Content
Keywords
Abstract
Objective: To evaluate the efficacy of dexlansoprazole 60mg on severe GERD patients after 8 weeks. Subject and method: This is a prospective, observational study in 38 patients over 18 years old, diagnosed with GERD grade B, C or D by gastroscopy according to Los Angeles classification, treated by dexlansoprazole 60mg/day in 108 Military Central Hospital from 3/2020 to 8/2020. Clinical symptoms, gastroscopy findings, side effects were evaluated after 4 weeks and 8 weeks of treatment. Result: 38 patients with average age of 52.08 ± 14.84 (years). After 8 weeks, all clinical symptoms alleviated, the prevalence of asymptomatic patients was 76.3%, GERDQ score decreased from 9.89 ± 2.26 to 6.34 ± 0.78 (p<0.05), esophageal erosive was completely healed on gastroscopy among 84.2% of patients. Drug’s side effects were diarrhea (5.3%), dizziness (2.6%), nausea (2.6%), no patient had to stop the drug due to side effects. Conclusion: Dexlansoprazole is an effective and safe drug in the treatment of gastroesophageal reflux disease.
Article Details
References
2. El-Serag HB, Sweet S, Winchester CC, et al (2014) Update on the epidemiology of gastroesophageal reflux disease: A systematic review. Gut 63: 871-880.
3. Fass R, Shapiro M, Dekel R et al (2005) Systematic review: Proton pump inhibitor failure in gastrooesophageal reflux disease-where next?. Aliment Pharmacol Ther 22: 79-94.
4. Hershcovici T, Jha LK and Fass R (2001) Dexlansoprazole MR - A review. Ann Med 43: 366-374.
5. Lê Thị Hoa (2006) Đặc điểm lâm sàng, nội soi, mô bệnh học và hiệu quả điều trị bằng esomeprazole ở bệnh nhân viêm thực quản do trào ngược. Luận văn thạc sỹ y học, Học viện Quân y.
6. Nguyễn Cảnh Bình và Mai Hồng Bàng (2009) Dị sản ruột và Helicobacter pylori tại đoạn nối thực quản dạ dày trong bệnh trào ngược dạ dày - thực quản. Tạp chí Khoa học Tiêu hóa Việt Nam, (17), tr. 76-79.
7. Michael Kukulka, Corey Eisenberg et al (2011) Comparator pH study to evaluate the singledose pharmacodynamics of dual delayed-release dexlansoprazole 60mg and delayed-release esomeprazole 40mg. Clinical and Experimental Gastroenterology 4: 213-220.
8. Sharma P, Shaheen NJ et al (2009) Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 29(7): 731-741.
9. Gremse D, Gold BD, Pilmer B, Hunt B, Korczowski B, Perez MC (2019) Dual delayed-release dexlansoprazole for healing and maintenance of healed erosive esophagitis: A safety study in adolescents. Dig Dis Sci 64(2): 493-502.
10. Fass R, Chey WD et al (2009) Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 29(12): 1261-1272.
11. Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK (2019) Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: A prospective randomized trial. Drug Design, Development and Therapy 13: 1347-1356.
12. Peura DA, Metz DC, Dabholkar AH et al (2009) Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel USAL delayed release formulation: Global clinical trial experience. Aliment Pharmacol Ther 30: 1010-1021.
Article Sidebar
